Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR KYBELLA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Kybella

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01032889 ↗ Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study Completed Kythera Biopharmaceuticals Phase 2 2009-12-01 Evaluation of the safety, tolerability and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
NCT01426373 ↗ Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area Completed Kythera Biopharmaceuticals Phase 3 2011-08-01 To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).
NCT01542034 ↗ Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area Completed Kythera Biopharmaceuticals Phase 3 2012-02-01 To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
NCT01546142 ↗ Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area Completed Kythera Biopharmaceuticals Phase 3 2012-03-01 To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
NCT02007434 ↗ Patient Experience Study of Deoxycholic Acid Injection Completed Kythera Biopharmaceuticals Phase 3 2013-12-01 The objectives of this study are to determine the safety of deoxycholic acid subcutaneous (SC) injections in the submental area and to evaluate the effects of four interventions, relative to placebo in the submental area, particularly with regard to assessment and management of pain, bruising, and swelling/edema.
NCT03241563 ↗ Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat Completed Allergan Phase 4 2016-04-01 The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. Canfield Vectra 3D imaging will be performed at baseline and at each follow up visit. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.
NCT03241563 ↗ Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat Completed Goldman, Butterwick, Fitzpatrick and Groff Phase 4 2016-04-01 The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. Canfield Vectra 3D imaging will be performed at baseline and at each follow up visit. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kybella

Condition Name

Condition Name for Kybella
Intervention Trials
Moderate or Severe Submental Fullness 5
Adiposity 3
Body Fat Disorder 1
Bra Strap Fat (BSF) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kybella
Intervention Trials
Obesity 3
Lipid Metabolism Disorders 1
Neurofibromatosis 1 1
Neurofibromatoses 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kybella

Trials by Country

Trials by Country for Kybella
Location Trials
United States 64
Canada 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kybella
Location Trials
California 8
Illinois 5
New York 4
Florida 4
Minnesota 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kybella

Clinical Trial Phase

Clinical Trial Phase for Kybella
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kybella
Clinical Trial Phase Trials
Completed 10
Recruiting 1
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kybella

Sponsor Name

Sponsor Name for Kybella
Sponsor Trials
Kythera Biopharmaceuticals 5
Allergan 3
Goldman, Butterwick, Fitzpatrick and Groff 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kybella
Sponsor Trials
Industry 9
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
McKesson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.